



War Room/DailyClout Pfizer Document Analysis


Follow The Money Team Micro-Report 4: Financial Performance Q1 2023

“This is an exciting time for Pfizer...,” stated CEO Albert Bourla. Yet, the company has seen a **LOSS** in market capitalization of **\$127.8 BILLION** since Dec. 2021. **Are investors starting to question Pfizer's approach?**

Pfizer reports that its mRNA COVID vaccine, Comirnaty®, manufacturing activities, performed on behalf of BioNTech, dropped 89% to only \$5 million quarter-over-quarter. Pfizer's stock is now trading well below \$41.12, its price on December 11, 2020, the date of the Emergency Use Authorization (EUA) approval for the company's "vaccine." Pfizer's Q1 2023 revenue was down 28.7% and Earnings Per Share were down 29% from Q1 2022. Pfizer's 2023 revenue guidance is about \$30 billion lower than it was 2022. The company's stock price has dropped from a high of \$59.48 on December 17, 2021, to a 52-week low of \$36.51 on May 17, 2023. This represents a 37% drop in just over 12 months.

Yet Pfizer CEO Albert Bourla states in Pfizer's Q1 2023 report that this is an “exciting time.” The Pfizer Board awarded Bourla compensation of \$33 million for 2022, an estimated 36% increase over 2021. Among other responsibilities, the Compensation Committee approves executive compensation, including CEO compensation.

The U.S. monovalent mRNA COVID-19 vaccines are no longer under EUA. Pfizer, per its Q1 2023 reporting, assumes no growth in market share for COVID-19 vaccinations. It states that education and awareness will help “absorption” of existing government vaccine supply. **Pfizer notes the Comirnaty's decrease in uptake is due to “fewer primary vaccinations and non-compliance.”** Pfizer is dependent upon sales increasing based upon compliance, education, and awareness. It does not appear from Pfizer's Q1 2023 presentation that future sales are market driven.



Clearly, investors are no longer buying what Pfizer is selling. **Pfizer, in its own words, reported 1,223 deaths and 1,290 Adverse Events of Special Interest in the first 90 days of its vaccine roll-out.** Those deaths and adverse events are not noted in Pfizer's financial reporting, which leaves its shareholders not fully informed.

Should investors trust Pfizer?

This report was written exclusively for DailyClout by the members of the War Room/DailyClout Pfizer Documents Analysis Project team. It may not be copied or republished without written permission from DailyClout or a full credit and link to DailyClout.io.

SOURCES:

Pfizer Q1 2023 Form 10-Q
<https://investors.pfizer.com/Investors/Financials/Quarterly-Results/>

May 2, 2023, Q1 Earnings Teleconference Slides
https://s28.q4cdn.com/781576035/files/doc_financials/2023/q1/Q1-2023-Earnings-Charts-FINAL.pdf

CEO Albert Bourla 2022 Pay
<https://seekingalpha.com/news/3948694-pfizer-ceo-pockets-33m-for-2022-after-36-percent-pay-hike>

Pfizer Revenue Year-Over-Year
<https://www.macrotrends.net/stocks/charts/PFE/pfizer/revenue>

Pfizer Compensation Committee
<https://investors.pfizer.com/Investors/Corporate-Governance/Board-Committees--Charters/default.aspx>

President Biden Lifts Federal Shot Mandate
<https://www.npr.org/2023/04/11/1169191865/biden-ends-covid-national-emergency>

Pfizer 5.3.6 Cumulative Analysis Post-Authorization Report
https://www.phmp.org/wp-content/uploads/2022/04/reissuue_5.3.6-postmarketing-experience.pdf

PFIZER STOCK PRICE:

12/17/21 - \$59.48
05/18/23 - \$36.48
Shares outstanding:
5.61 billion

Follow the Money Team



22July23